Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
View stock
VS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
View stock

Stock highlights

Stock comparison highlights
Stock name
NeoGenomicsAbbVie
Last price
$16.35$276.47
Currency
USD
USD
$2.1B$480B
-76.66
-$0.40$3.54
1.750.28
0$6.83
02.55%
Sector
HealthHealth
Employees
2,50057,000
Ticker
$NEO$ABBV
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $NEO or $ABBV on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.